Charles River Laboratories (CRL)vsNatera Inc (NTRA)
CRL
Charles River Laboratories
$177.62
-2.23%
HEALTHCARE · Cap: $8.97B
NTRA
Natera Inc
$194.24
-11.64%
HEALTHCARE · Cap: $30.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Charles River Laboratories generates 74% more annual revenue ($4.02B vs $2.31B). CRL leads profitability with a -3.6% profit margin vs -9.0%. CRL earns a higher WallStSmart Score of 39/100 (F).
CRL
Hold39
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+21.0%
Fair Value
$210.15
Current Price
$177.62
$32.53 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 39.8% year-over-year
Areas to Watch
Distress zone — elevated risk
Operating margin of 4.5%
Weak financial health signals
ROE of -4.2% — below average capital efficiency
Trading at 15.8x book value
0.0% earnings growth
ROE of -14.3% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : CRL
The strongest argument for CRL centers on PEG Ratio, Price/Book. PEG of 0.13 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth. Revenue growth of 39.8% demonstrates continued momentum.
Bear Case : CRL
The primary concerns for CRL are Altman Z-Score, Operating Margin, Piotroski F-Score.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
CRL profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.57 — expect wider price swings.
NTRA is growing revenue faster at 39.8% — sustainability is the question.
NTRA generates stronger free cash flow (38M), providing more financial flexibility.
Bottom Line
CRL scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Charles River Laboratories
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?